PRISMAP scientific publications

Publications in peer-reviewed journals, conference proceedings, book chapters and books.

1.
Gamma-ray spectrometry measurements for quality assessment of scandium-47 produced by neutron irradiation of calcium-46.
Applied Radiation and Isotopes 229, 112408 (2026). doi:10.1016/j.apradiso.2025.112408. Archive: pubmed
2.
Radiobiological investigations of a [212Pb]Pb-carbonic anhydrase IX-targeting small-molecule ligand in renal cell carcinoma and colorectal cancer models.
International Journal of Radiation Biology 102, 127–137 (2026). doi:10.1080/09553002.2025.2595630. Archive: pubmed
3.
Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Theranostics 16, 2887–2917 (2026). doi:10.7150/thno.126086. Archive: HAL
4.
Scandium-47 as a radionuclide precursor: Feasibility of production in a 47Ca/47Sc generator-like system.
Nuclear Medicine and Biology 152-153, 109595 (2026). doi:10.1016/j.nucmedbio.2025.109595. Archive: pubmed
5.
Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001.
Scientific Reports (2025). doi:10.1038/s41598-025-29785-7. Archive: pubmed
6.
CERN-MEDICIS: A unique facility for the production of radionuclides for medical research.
1071–1074 pages, 0.73 MB (2025). doi:10.18429/JACOW-IPAC2025-TUPB047
7.
Navigating the safety profile of Actinium-225 targeted alpha therapy: a comprehensive review.
Clinical and Translational Imaging (2025). doi:10.1007/s40336-025-00733-9. Archive: zenodo
8.
Validation of ICP-OES and γ-spectrometry methodologies for quality assessment of 67Cu from cyclotron production via the 70Zn(p,α)67Cu nuclear reaction.
Journal of Radioanalytical and Nuclear Chemistry 334, 5637–5648 (2025). doi:10.1007/s10967-025-10270-4. Archive: Orbit
9.
Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models.
Medical Oncology 42, 362 (2025). doi:10.1007/s12032-025-02925-9. Archive: TREPO
10.
To be GMP or not to be– a radionuclide’s question.
EJNMMI Radiopharmacy and Chemistry 10, (2025). doi:10.1186/s41181-025-00369-0. Archive: pubmed
11.
Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS.
Scientific Reports 15, (2025). doi:10.1038/s41598-025-02277-4. Archive: PMC
12.
Electron-gamma decay spectroscopy of152 Tb.
Physica Scripta 100, 065308 (2025). doi:10.1088/1402-4896/add812. Archive: zenodo
13.
Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161.
EJNMMI Radiopharmacy and Chemistry 10, 18 (2025). doi:10.1186/s41181-025-00339-6. Archive: pubmed
14.
Nanolayer of Monocrystalline Si Towards Nanodosimetry of Electron Radiation.
in Joint 20th Nordic-Baltic Conference on Biomedical Engineering & 24th Polish Conference on Biocybernetics and Biomedical Engineering (eds. Ladyzynski, P., Pijanowska, D. G. & Liebert, A.) 267–277 (Springer Nature Switzerland, 2025). doi:10.1007/978-3-031-96538-8_22
15.
Towards complete decay spectroscopy of 152Tb.
Radiation Physics and Chemistry 232, 112641 (2025). doi:10.1016/j.radphyschem.2025.112641. Archive: zenodo
16.
Production of 67Cu at a biomedical cyclotron via 70Zn(p,α)67Cu reaction and its evaluation in a preclinical study using small animal SPECT/CT.
Applied Radiation and Isotopes 215, 111551 (2025). doi:10.1016/j.apradiso.2024.111551. Archive: Orbit
17.
Two-step extraction chromatography separation of 161Tb from 160Gd-enriched irradiated target material and verification of the [161Tb]TbCl3 suitability for radiolabelling.
Applied Radiation and Isotopes 226, 112144 (2025). doi:10.1016/j.apradiso.2025.112144. Archive: PMC
18.
Novel radionuclides: demand, production and distribution for translational research in Europe.
EJNMMI Radiopharmacy and Chemistry 9, 85 (2024). doi:10.1186/s41181-024-00318-3. Archive: pubmed
19.
Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting 43Sc, 61Cu and 45Ti.
EJNMMI Physics 11, 98 (2024). doi:10.1186/s40658-024-00699-z. Archive: PMC
20.
Scandium thermal release from activated natnatTi and natnatV target materials in mixed particle fields: Investigation of parameters relevant for isotope mass separation.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 553, 165400 (2024). doi:10.1016/j.nimb.2024.165400. Archive: CDS
21.
First ion source at ISOL@MYRRHA with an improved thermal profile - Theoretical considerations.
Journal of Physics: Conference Series 2743, 012065 (2024). doi:10.1088/1742-6596/2743/1/012065. Archive: LIRIAS
22.
Target Development towards First Production of High-Molar- Activity 44gSc and 47Sc by Mass Separation at CERN-MEDICIS.
Pharmaceuticals 17, 390 (2024). doi:10.3390/ph17030390. Archive: PMC
23.
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework.
EJNMMI Radiopharmacy and Chemistry 9, 2 (2024). doi:10.1186/s41181-023-00230-2. Archive: PMC
24.
Synthesis and Preclinical Evaluation of PSMA-Targeted 111 In-Radioconjugates Containing a Mitochondria-Tropic Triphenylphosphonium Carrier.
Molecular Pharmaceutics 21, 216–233 (2024). doi:10.1021/acs.molpharmaceut.3c00787. Archive: SCHOLAR
25.
CERN-MEDICIS: Operational indicators to support the production of new medical radionuclides by mass-separation.
Journal of Physics: Conference Series 2687, 082039 (2024). doi:10.1088/1742-6596/2687/8/082039. Archive: LIRIAS
26.
The SPES laser ion source: Time structure, laser enhancement and efficiency measurements with gallium at ISOLDE Offline 2.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 548, 165249 (2024). doi:10.1016/j.nimb.2024.165249. Archive: CDS
27.
Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.
Nuclear Medicine and Biology 108990 (2024). doi:10.1016/j.nucmedbio.2024.108990. Archive: zenodo
28.
Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Theranostics 14, 1720–1743 (2024). doi:10.7150/thno.92775. Archive: PMC
29.
Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide.
Frontiers in Chemistry 11, 1288588 (2023). doi:10.3389/fchem.2023.1288588. Archive: BORIS
30.
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?.
EJNMMI Radiopharmacy and Chemistry 8, 27 (2023). doi:10.1186/s41181-023-00211-5. Archive: PMC
31.
Resonant laser ionization and mass separation of 225Ac.
Scientific Reports 13, 1347 (2023). doi:10.1038/s41598-023-28299-4. Archive: CDS
32.
DFT calculations of Ti-based molecules clustering with Ar for laser-based enrichment of stable isotopes.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 141–143 (2023). doi:10.1016/j.nimb.2023.05.040. Archive: CDS
33.
Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 542, 137–143 (2023). doi:10.1016/j.nimb.2023.05.008. Archive: CDS
34.
Weak Electron Emission of Nanodiamond Irradiated with High Energy Electrons.
in 19th Nordic-Baltic Conference on Biomedical Engineering and Medical Physics (eds. Dekhtyar, Y. & Saknite, I.) 89, 293–303 (Springer Nature Switzerland, 2023). doi:10.1007/978-3-031-37132-5_37
35.
Determination of the Terbium-152 half-life from mass-separated samples from CERN-ISOLDE and assessment of the radionuclide purity.
Applied Radiation and Isotopes 202, 111044 (2023). doi:10.1016/j.apradiso.2023.111044. Archive: PMC
36.
First on-line application of the high-resolution spectroscopy laser ion source PI-LIST at ISOLDE.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 8–12 (2023). doi:10.1016/j.nimb.2023.04.057
37.
On the feasibility of online terbium extraction at ISOL@MYRRHA.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 249–252 (2023). doi:10.1016/j.nimb.2023.05.034
38.
Can we reach suitable 161Tb purity for medical applications using the 160Gd(d,n) reaction?.
Applied Radiation and Isotopes 200, 110927 (2023). doi:10.1016/j.apradiso.2023.110927. Archive: HAL
39.
Improved procedures for production and purification of 135La from enriched [135Ba]BaCO3 on a 16.5 MeV cyclotron.
Applied Radiation and Isotopes 192, 110612 (2023). doi:10.1016/j.apradiso.2022.110612. Archive: DTU Orbit
40.
Study of terbium production from enriched Gd targets via the reaction 155Gd(d,2n)155Tb.
Applied Radiation and Isotopes 201, 110996 (2023). doi:10.1016/j.apradiso.2023.110996. Archive: HAL
41.
Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State.
Diagnostics 12, 3176 (2022). doi:10.3390/diagnostics12123176. Archive: PMC
42.
Thermal and Structural Characterization of a Titanium Carbide/Carbon Composite for Nuclear Applications.
Materials 15, 8358 (2022). doi:10.3390/ma15238358. Archive: PMC
43.
Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [153Sm]Sm-DOTA-TATE.
Pharmaceutics 14, 2566 (2022). doi:10.3390/pharmaceutics14122566. Archive: SCK CEN Publications
44.
Excitation functions of deuteron induced nuclear reactions on dysprosium targets for the production of the theranostic relevant isotopes of terbium.
The European Physical Journal Plus 137, 1180 (2022). doi:10.1140/epjp/s13360-022-03378-z. Archive: HAL
45.
67Cu Production Capabilities: A Mini Review.
Molecules 27, 1501 (2022). doi:10.3390/molecules27051501. Archive: PMC
46.
Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS.
Applied Radiation and Isotopes 190, 110480 (2022). doi:10.1016/j.apradiso.2022.110480. Archive: cds
47.
Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS.
Frontiers in Medicine 8, 712374 (2021). doi:10.3389/fmed.2021.712374. Archive: PMC
48.
Emerging Radionuclides in a Regulatory Framework for Medicinal Products – How Do They Fit?.
Frontiers in Medicine 8, 678452 (2021). doi:10.3389/fmed.2021.678452. Archive: PMC
49.
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy.
Journal of Nuclear Medicine 62, 1495–1503 (2021). doi:10.2967/jnumed.120.261016. Archive: PMC